|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PHLDB2 |
Gene summary for PHLDB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PHLDB2 | Gene ID | 90102 |
| Gene name | pleckstrin homology like domain family B member 2 | |
| Gene Alias | LL5b | |
| Cytomap | 3q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q86SQ0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90102 | PHLDB2 | CCI_1 | Human | Cervix | CC | 1.53e-03 | 9.03e-01 | 0.528 |
| 90102 | PHLDB2 | CCI_3 | Human | Cervix | CC | 7.19e-05 | 6.17e-01 | 0.516 |
| 90102 | PHLDB2 | CCII_1 | Human | Cervix | CC | 7.87e-06 | 3.42e-01 | 0.3249 |
| 90102 | PHLDB2 | sample1 | Human | Cervix | CC | 3.20e-22 | 8.14e-01 | 0.0959 |
| 90102 | PHLDB2 | T1 | Human | Cervix | CC | 6.64e-45 | 9.32e-01 | 0.0918 |
| 90102 | PHLDB2 | LZE4T | Human | Esophagus | ESCC | 1.39e-33 | 1.16e+00 | 0.0811 |
| 90102 | PHLDB2 | LZE7T | Human | Esophagus | ESCC | 6.41e-08 | 1.60e+00 | 0.0667 |
| 90102 | PHLDB2 | LZE8T | Human | Esophagus | ESCC | 3.86e-08 | 3.59e-01 | 0.067 |
| 90102 | PHLDB2 | LZE20T | Human | Esophagus | ESCC | 4.68e-02 | 1.11e-01 | 0.0662 |
| 90102 | PHLDB2 | LZE21T | Human | Esophagus | ESCC | 5.44e-07 | 3.37e-01 | 0.0655 |
| 90102 | PHLDB2 | P2T-E | Human | Esophagus | ESCC | 5.40e-04 | -1.07e-01 | 0.1177 |
| 90102 | PHLDB2 | P4T-E | Human | Esophagus | ESCC | 1.44e-16 | 7.51e-01 | 0.1323 |
| 90102 | PHLDB2 | P5T-E | Human | Esophagus | ESCC | 1.71e-14 | 5.23e-01 | 0.1327 |
| 90102 | PHLDB2 | P9T-E | Human | Esophagus | ESCC | 2.88e-34 | 1.29e+00 | 0.1131 |
| 90102 | PHLDB2 | P10T-E | Human | Esophagus | ESCC | 3.36e-07 | 2.54e-01 | 0.116 |
| 90102 | PHLDB2 | P11T-E | Human | Esophagus | ESCC | 1.31e-24 | 1.24e+00 | 0.1426 |
| 90102 | PHLDB2 | P12T-E | Human | Esophagus | ESCC | 3.70e-04 | 2.27e-01 | 0.1122 |
| 90102 | PHLDB2 | P15T-E | Human | Esophagus | ESCC | 2.04e-23 | 6.81e-01 | 0.1149 |
| 90102 | PHLDB2 | P16T-E | Human | Esophagus | ESCC | 3.44e-09 | 5.54e-02 | 0.1153 |
| 90102 | PHLDB2 | P17T-E | Human | Esophagus | ESCC | 2.22e-06 | 4.54e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:001081010 | Cervix | CC | regulation of cell-substrate adhesion | 69/2311 | 221/18723 | 8.57e-14 | 5.69e-11 | 69 |
| GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
| GO:01501159 | Cervix | CC | cell-substrate junction organization | 37/2311 | 101/18723 | 3.20e-10 | 4.46e-08 | 37 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:00070448 | Cervix | CC | cell-substrate junction assembly | 34/2311 | 95/18723 | 3.35e-09 | 3.45e-07 | 34 |
| GO:00019528 | Cervix | CC | regulation of cell-matrix adhesion | 40/2311 | 128/18723 | 1.32e-08 | 1.04e-06 | 40 |
| GO:00071608 | Cervix | CC | cell-matrix adhesion | 60/2311 | 233/18723 | 1.58e-08 | 1.23e-06 | 60 |
| GO:00071626 | Cervix | CC | negative regulation of cell adhesion | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
| GO:00443193 | Cervix | CC | wound healing, spreading of cells | 17/2311 | 34/18723 | 9.86e-08 | 5.25e-06 | 17 |
| GO:00905053 | Cervix | CC | epiboly involved in wound healing | 17/2311 | 34/18723 | 9.86e-08 | 5.25e-06 | 17 |
| GO:00905043 | Cervix | CC | epiboly | 17/2311 | 35/18723 | 1.70e-07 | 7.93e-06 | 17 |
| GO:006157210 | Cervix | CC | actin filament bundle organization | 44/2311 | 161/18723 | 2.08e-07 | 9.34e-06 | 44 |
| GO:005101710 | Cervix | CC | actin filament bundle assembly | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
| GO:01501169 | Cervix | CC | regulation of cell-substrate junction organization | 25/2311 | 71/18723 | 5.58e-07 | 2.06e-05 | 25 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PHLDB2 | SNV | Missense_Mutation | novel | c.1172N>T | p.Asp391Val | p.D391V | Q86SQ0 | protein_coding | deleterious(0) | benign(0.203) | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD |
| PHLDB2 | SNV | Missense_Mutation | novel | c.3502N>A | p.Asp1168Asn | p.D1168N | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PHLDB2 | SNV | Missense_Mutation | c.359N>A | p.Gly120Glu | p.G120E | Q86SQ0 | protein_coding | tolerated_low_confidence(0.09) | benign(0.018) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.1708N>G | p.Ile570Val | p.I570V | Q86SQ0 | protein_coding | tolerated(0.1) | benign(0.255) | TCGA-B6-A0WV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.604C>T | p.Pro202Ser | p.P202S | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.549) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| PHLDB2 | SNV | Missense_Mutation | c.1690N>C | p.Glu564Gln | p.E564Q | Q86SQ0 | protein_coding | deleterious(0.05) | benign(0.388) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.1608N>T | p.Arg536Ser | p.R536S | Q86SQ0 | protein_coding | tolerated(0.07) | benign(0.057) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| PHLDB2 | SNV | Missense_Mutation | c.3134N>T | p.Ala1045Val | p.A1045V | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| PHLDB2 | SNV | Missense_Mutation | novel | c.7N>A | p.Glu3Lys | p.E3K | Q86SQ0 | protein_coding | deleterious_low_confidence(0) | benign(0.214) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PHLDB2 | SNV | Missense_Mutation | novel | c.3132N>T | p.Gln1044His | p.Q1044H | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |